Interface, Inc. filed a Form 8-K with the SEC on November 6, 2026, reporting its financial results for the third quarter of 2026 and furnishing an updated investor slide presentation.
Atmus Filtration Technologies Inc. filed a Form 8-K with the SEC on November 6, 2026, disclosing third-quarter 2026 financial results and the approval of a new $300 million stock repurchase program, effective immediately.
Perspective Therapeutics, Inc. filed a Form 8-K on November 6, 2026, disclosing that on November 5, 2026, the company issued a press release and posted presentations announcing incremental clinical trial data for its VMT-α-NET program at the NANETS 2026 Multidisciplinary NET Medical Symposium.
Precision BioSciences, Inc. filed a Form 8-K on November 6, 2026, disclosing the pricing and terms of a public offering of common stock and pre-funded warrants entered into on November 5, 2026, with estimated net proceeds of approximately $116.5 million.
HSBC Holdings plc filed a Form 6-K on 6 November 2026 announcing an increase to the maximum tender amount of its cash tender offer for its outstanding 6.000% Perpetual Subordinated Contingent Convertible Securities, raising the cap from $1,000,000,000 to $1,500,000,000.
Diageo plc filed a Form 6-K with the SEC on 6 November 2026 reporting that all 25 resolutions put to shareholders at its Annual General Meeting held on 5 November 2026 were passed.
Essent Group Ltd. filed a Form 8-K with the SEC on November 6, 2026, disclosing the issuance of a press release announcing its financial results for the quarter ended September 30, 2026.
Silynxcom Ltd. Director and VP Marketing and Israel Sales Gal Nir Klein filed a Form 4 on November 6, 2026, disclosing open-market purchases of ordinary shares on November 3 and November 4, 2026.
Director David R. Epstein filed a Form 4 with the SEC on November 6, 2026, disclosing three open-market purchases of AgomAb Therapeutics NV common shares made on November 5, 2026, totaling 15,000 shares acquired at prices ranging from $6.81 to $6.98 per share.
Director John Moore Fowler filed a Form 4 with the SEC on November 5, 2026, disclosing the sale of 1,575 shares of StoneX Group Inc. common stock under a Rule 10b5-1 plan.